5van der Goes MC,Jacobs JW,Boers M,et al.Monitoring adverse events of low-dose glucocorticoid therapy:EULAR recommendations for clinical trials and daily practice[J].Ann Rheum Dis,2010,69:1913-1919.
6Duru N,van der Goes MC,Jacobs JW,et al.EULAR evidencebased and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases[J].Ann Rheum Dis,2013,72:1905-1913.
7Hahn BH,McMahon MA,Wilkinson A,et al.American College of Rheumatology guidelines for screening,treatment,and management of lupus nephritis[J].Arthritis Care Res (Hoboken),2012,64:797-808.
9Walling HW,Sontheimer RD.Cutaneous lupus erythematosus:issues in diagnosis and treatment[J].Am J Clin Dermatol,2009,10:365-381.
10Boumpas DT,Austin HA 3rd,Vaughn EM,et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis[J].Lancet,1992,340:741-745.
